W. L. Gore & Associates, Inc.

Gore Enterprise Holdings, Inc.

The University of Texas System

Ventana Medical Systems, Inc.

Ge Hybrid Technologies, LLC

Other

Paul D Drumheller

Robert L Cleek

Edward H Cully

Theresa A Holland

Mei Li

William B Johnson

Xin Kang Chen

Jack J Hegenbarth

Rachel Radspinner

Wen K Liu

Ping Xu

Brian Kram

Jeffrey Alan Hubbell

Amarpreet S Sawhney

Christopher Bieniarz

Donald Leo Elbert

Brian Howard Kram

Jennifer L Hill-West

Sanghamitra Chowdhury

Karin Leontein

Per Antoni

Lauren Zambotti

Todd J Johnson

Bernadette Parsons

Peter D Traylor

Cody L Hartman

Jeffrey B Duncan

Charles J Flynn

Charles David Claude

Carey V Campbell

Benjamin M Trapp

Charles F White

Bruce M Steinhaus

Nathan L Friedman

Krzysztof Pietrzak

Thomas G Triebes

Stanley L Mish

Ted R Farnsworth

Mark D Butler

Thane L Kranzler

Byron K Hayes

Alonzo D Cook

James F Davidson

Roy Biran

Terry A Hubbard

Nora Mardirosian

Paul B Jennings, Jr

Daniel L Crandall

Gregory LoStracco

Lars Vincent

Krzysztof R Pietrzak

Gregory Lostracco

Charles D Claude

Charles Flynn

Bruce Steinhaus

The present disclosure is directed toward composite materials comprising high aspect ratio habits of drug crystals which can be partially or fully extending into a substrate, and additionally, can be projecting from a substrate at an angle of about 20° to about 90°. The present disclosure is directed toward medical devices, such as medical balloons, comprising said composite and methods of using and making the same. The described composite can be used for the local treatment of vascular disease. The present disclosure is also directed toward paclitaxel crystals with a hollow acicular habit.

Porous composites with high-aspect ratio crystals

An implantable containment apparatus for receiving and retaining a plurality of cells for insertion into a patient, such as into a tissue bed, is disclosed. The device includes a chamber having structural spacers therein to maintain an average distance between the first interior surface and the second interior surface of the chamber and to define at least one reservoir space for the placement of cells within the chamber.

Cell encapsulation devices containing structural spacers

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

Drug composition and coating

An implantable containment apparatus for receiving and retaining a biological moiety or a therapeutic device within a tissue bed is disclosed. The device includes a shaping element to maintain the device in a generally toroidal configuration and to return the apparatus to that configuration after deformation. The apparatus can be placed in a host tissue with minimal trauma to the patient. Methods for implanting and using the apparatus are also disclosed.

Implantable apparatus for retention of biological moieties

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.

Polytetrafluoroethylene co-polymer emulsions

According to the invention there is provided inter alia a medical device for delivering a paclitaxel to a tissue, the device the device having a coating layer applied to a surface of the device, the coating layer comprising components i), ii) and iii), wherein component i) is a therapeutic agent which is paclitaxel; and component ii) is urea or a pharmaceutically acceptable salt thereof, or a urea derivative or a pharmaceutically acceptable salt thereof; and component iii) is succinic acid, glutaric acid or caffeine, or a pharmaceutically acceptable salt of any one thereof.

The present disclosure is directed toward composite materials comprising high aspect ratio habits of drug crystals which can be partially or fully extending into a substrate, and additionally, can be projecting from a substrate at an angle of about 20&#xb0; to about 90&#xb0;. The present disclosure is directed toward medical devices, such as medical balloons, comprising said composite and methods of using and making the same. The described composite can be used for the local treatment of vascular disease. The present disclosure is also directed toward paclitaxel crystals with a hollow acicular habit.

According to the invention there is provided inter alia a medical device for delivering a paclitaxel to a tissue, the device the device having a coating layer applied to a surface of the device, the coating layer comprising components i), ii) and iii), wherein

The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.

Articles and methods of treating vascular conditions

The present disclosure is directed to a class of fluorinated copolymers, such as a PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.

Coatings for a surface, especially a priming coating, of the present invention have been found to be durable, resistant to oxidative degradation, erosion and depolymerization, stable to sterilization and low particulating, and are easily applied to the required surface of a substrate in a surface-independent manner. Such coatings, when used as priming coatings to be coated with a subsequent coating, in at least some embodiments, form exterior coatings which are also highly durable and are stable to sterilization and aging.

Coating for a surface

The invention is directed to eluting medical devices that enable consistent 'on-demand' delivery of therapeutic agents to a vessel. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and an outer sheath with a variably permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during expansion of the expandable member, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site.

Eluting medical devices

Growing community of inventors

Flagstaff, AZ, United States of America

Paul D Drumheller